Oruka Therapeutics ORKA
NASDAQ ORKA
$83.18 -0.11 (-0.13%)
As of: Oct 1, 2026 · 10:42 AM EDT

Oruka Therapeutics (ORKA) Preferred Shares (2024 - 2026)

Updated

Oruka Therapeutics (ORKA) recorded Preferred Shares of $5.86 million in Q2 2026, unchanged from $5.86 million a year earlier and unchanged from the prior quarter.

Analysis

Oruka Therapeutics (ORKA) Preferred Shares (2024 - 2026) Analysis & Trends

At the end of FY2025, Oruka Therapeutics reported Preferred Shares of $2.93 million, down 50.0% from FY2024.

  • Across earlier years, Preferred Shares came in at $5.86 million in FY2024.
  • Quarterly Preferred Shares has ranged from $2.93 million in Q4 2025 to $55.77 million in Q3 2024 over the past five years.
  • Per Business Quant, the preceding three quarters came in at $5.86 million (Q1 2026), $2.93 million (Q4 2025) and $5.86 million (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Shares (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn -
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn -
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn -
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn -
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn -
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn -
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn -
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn -
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn -
10 Oruka Therapeutics 5.24 Bn 3.29 Bn - 5.86 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 5.86 Mn
Mar 31, 2026 5.86 Mn
Dec 31, 2025 2.93 Mn
Sep 30, 2025 5.86 Mn
Jun 30, 2025 5.86 Mn
Mar 31, 2025 5.86 Mn
Dec 31, 2024 5.86 Mn
Sep 30, 2024 55.77 Mn
API Access

Oruka Therapeutics Preferred Shares API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=preferred-shares&ticker=ORKA&period=max&api_key=YOUR_API_KEY